STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy
Abstract As cancer continues to rank among the leading causes of death, the demand for novel treatments has never been higher. Immunotherapy shows promise, yet many solid tumors such as pancreatic cancer or glioblastoma remain resistant. In these, the “cold” tumor microenvironment with low immune ce...
Saved in:
| Main Authors: | Laura Gehrcken, Christophe Deben, Evelien Smits, Jonas R.M. Van Audenaerde |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202500296 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy
by: Xiaoyan Qi, et al.
Published: (2024-12-01) -
The human STING agonist E7766 induces immunogenic tumor clearance, independent of tumor-intrinsic STING expression in the KRASG12D/+ Trp53−/− murine model of sarcoma
by: Karys M. Hildebrand, et al.
Published: (2025-12-01) -
Progress Update on STING Agonists as Vaccine Adjuvants
by: Yanru Shen, et al.
Published: (2025-03-01) -
Conjugated STING agonists
by: Shuhao Qu, et al.
Published: (2025-06-01) -
Bioinformatic characterization of STING expression in hematological malignancies reveals association with prognosis and anti-tumor immunity
by: Xiang-mei Wen, et al.
Published: (2025-02-01)